Skip to main content

Acurx Pharmaceuticals, Inc.

corporate_fare Company Profile

Acurx Pharmaceuticals, Inc.

ACXP·NASDAQ·Life Sciences·CIK 0001736243

Acurx Pharmaceuticals is a late-stage biopharmaceutical company that develops a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company's strategy involves creating antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC). This action inhibits DNA replication, leading to Gram-positive bacterial cell death. Acurx Pharmaceuticals' research and development (R&D) pipeline includes antibiotic product candidates targeting Gram-positive bacteria such as Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP), and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). These bacterial targets are identified as priority pathogens by the World Health Organization (WHO), the United States (U.S.) Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA), requiring new antibiotics to address antimicrobial resistance (AMR). The CDC estimates that, in the U.S., antibiotic-resistant pathogens infect one individual every 11 seconds and result in one death every 15 minutes. According to the WHO Fact Sheet (November 2023), bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to 4.95 million deaths. The company believes it is developing the first DNA pol IIIC inhibitor ready to enter Phase 3 clinical trials and has clinically validated the efficacy of its lead pol IIIC antibiotic candidate in a Phase 2 clinical trial. Pol IIIC is the primary catalyst for DNA replication of several Gram-positive bacterial cells.

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ACXP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ACXP spans 10-Q, 424B3, S-1, 8-K.

Recent high-impact activity:

  • Acurx Q3 Loss Widens to $2.58M as Going-Concern Doubt Persists on $9.7M Cash
  • Acurx Enrolls First Patient in PATHFINDER Trial for Recurrent C. difficile
  • FDA Conditionally Accepts Acurx's CIFBEZY Brand Name for Ibezapolstat
  • Acurx Q2 Loss Narrows to $2.25M; FDA Path for Ibezapolstat Advances
  • Acurx Q2 Loss Steady at $2.3M; Cash $10.7M, Going Concern Warning Reiterated

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$7.97M
Diluted EPS
-$5.32
Op. Cash Flow
-$6.79M
Operating Income
-$8.09M
Cash & Equivalents
$7.56M
Debt / Equity
0.00×
Shares Outstanding
2.35M sh
Source: 10-K · filed 2026-03-12 · accession 0001104659-26-027052

Short Interest & Short Volume

1.63 days to cover

FINRA reported short interest of 97,568 shares in ACXP as of the October 30, 2026 settlement, a 7.5% increase from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 40.0% of ACXP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)97,568 shares as of October 30, 2026
Change vs prior period▲ 7.5%
Days to cover1.63 at avg daily volume of 60,021
Daily short volume (FINRA facilities)40.0% of 95,096 shares on November 20, 2026
5-day average short volume38.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ACXP, detected from its recent SEC filings · based on capital-structure filings through 2026-09-08.

1 shelf registration

Additional 1.5M Shares Registered for Resale · Remaining Proceeds Up to $2.8M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$1.1 +5.77% today
52-week range · as of 2026-11-12 $0.92 – $7.54
Market cap
$6.3M
Volume
154.3K (1.4× avg)
3-mo avg 108.5K
Live data · 2026-11-22 02:39 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACXP - Latest Insights

ACXP
Nov 12, 2026, 6:46 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.966
Real-time Price: $1.10 info
Change: +$0.134 (+14%) info
Market Cap: $6.3M info
ACXP
Sep 29, 2026, 8:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.10 info
Change: -$0.3121 (-22%) info
Market Cap: $6.3M info
ACXP
Aug 17, 2026, 8:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $1.10 info
Change: -$0.260 (-19%) info
Market Cap: $6.3M info
ACXP
Aug 14, 2026, 7:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.10 info
Change: -$0.530 (-33%) info
Market Cap: $6.3M info
ACXP
Aug 13, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $1.10 info
Change: -$0.4475 (-29%) info
Market Cap: $6.3M info
ACXP
Aug 03, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $1.10 info
Change: -$0.350 (-24%) info
Market Cap: $6.3M info
ACXP
Jul 08, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $1.10 info
Change: -$0.3754 (-25%) info
Market Cap: $6.3M info
ACXP
May 19, 2026, 12:25 PM EDT
Source: Access Newswire
Importance Score:
8
Price at Filing: $1.78
Real-time Price: $1.10 info
Change: -$0.680 (-38%) info
Market Cap: $6.3M info
ACXP
May 12, 2026, 3:05 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $1.99
Real-time Price: $1.10 info
Change: -$0.890 (-45%) info
Market Cap: $6.3M info
ACXP
May 12, 2026, 3:04 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $1.99
Real-time Price: $1.10 info
Change: -$0.890 (-45%) info
Market Cap: $6.3M info
ACXP
May 11, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.10 info
Change: -$1.08 (-50%) info
Market Cap: $6.3M info
ACXP
May 11, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $1.10 info
Change: -$1.11 (-50%) info
Market Cap: $6.3M info
ACXP
May 04, 2026, 4:09 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $1.10 info
Change: -$0.980 (-47%) info
Market Cap: $6.3M info
ACXP
May 04, 2026, 4:08 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $1.10 info
Change: -$0.980 (-47%) info
Market Cap: $6.3M info
ACXP
Apr 16, 2026, 8:14 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.67
Real-time Price: $1.10 info
Change: -$1.57 (-59%) info
Market Cap: $6.3M info
ACXP
Apr 16, 2026, 8:13 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.67
Real-time Price: $1.10 info
Change: -$1.57 (-59%) info
Market Cap: $6.3M info
ACXP
Mar 12, 2026, 4:06 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $5.13
Real-time Price: $1.10 info
Change: -$4.03 (-79%) info
Market Cap: $6.3M info
ACXP
Mar 09, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.38
Real-time Price: $1.10 info
Change: -$0.280 (-20%) info
Market Cap: $6.3M info
ACXP
Mar 09, 2026, 8:59 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.38
Real-time Price: $1.10 info
Change: -$0.2809 (-20%) info
Market Cap: $6.3M info
ACXP
Feb 11, 2026, 4:21 PM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.96
Real-time Price: $1.10 info
Change: -$0.860 (-44%) info
Market Cap: $6.3M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets